

Review

Not peer-reviewed version

Toward Smarter Drug Delivery Solutions via Liposomal Carriers, Effervescent Formulations, and Extracellular Vesicles

[Ashutosh Sengar](#)*

Posted Date: 31 July 2025

doi: 10.20944/preprints202507.2595.v1

Keywords: Smart Nanocarriers; Liposomal Drug Delivery; pH-Responsive Nanoparticles; Extracellular Vesicles



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Toward Smarter Drug Delivery Solutions via Liposomal Carriers, Effervescent Formulations, and Extracellular Vesicles

Sengar Ashutosh

Independent Researcher, India; Ashutoshsengar26567@gmail.com

Abstract

Smart drug delivery systems represent a transformative paradigm in modern pharmacology, aimed at enhancing medical efficacy, reducing systemic side effects, and distributing medicines in a site-specific and controlled manner. This review consolidates the latest progression in liposomal technologies, polymorphic nanosystems and programmable lipid systems that provide mechanical accuracy in targeted therapy. Integration of pH-sensitive and pegylated nanoparticles allows selective release in tumor microenvironment, significantly improves bioavailability and reduces toxicity. Magnetic microbots and nanotechnology are now emerging as active navigational equipment for drug distribution in hard-to-reach areas, providing new opportunities in minimal invasive remedies. In parallel, versatile platforms such as microneedles and the effervescent systems improve drug stability, patient compliance, and treatment flexibility. In addition, bio-inspired innovations such as mimicking of extracellular vesicles mimic the physical transport system and make extraordinary promises for clinical translation due to their bio-diagnosis and targeting capacity. Safety and scalability remains important for regulatory acceptance, which induced integrated approaches related to biological, engineering and clinical science. By analyzing the developments prepared from recent and relevant studies, this paper offers a comprehensive perspective on the current trends, challenges and future instructions in the field of smart nanocarriers and bioinspired drug delivery platforms. The collective insight provides a roadmap towards more efficient, safe and patient-specific medical strategies.

Keywords: smart nanocarriers; liposomal drug delivery; pH-responsive nanoparticles; extracellular vesicles

1. Introduction to Smart Drug Delivery Systems

Smart drug delivery systems represent a transformational change as to how medical agents are administered, which enables accurate targeting of specific tissues or cells while reducing systemic toxicity [1]. These advanced systems include a series of liposomes, polymeric nanosystems and vesicular structures such as nanocarriers, each of which is designed for controlled release, increased bioavailability, and off-target effect [1].

Rapid progress in nanotechnology has fuel innovative designs that respond to stimuli such as pH, temperature, or specific enzymes, allowing the drug release to closely align with physical needs and thus pursue individual medicine [2]. This personalization enables the treatment of individual genetic and molecular profiles, improving medical results by reducing adverse effects [2].

Especially in cancer therapy, nanotechnology provides opportunities to remove biological barriers and accumulate selected drugs in tumors, represents a significant improvement on traditional chemotherapy approaches [3]. However, the region faces complex manufacturing, challenges related to regulatory barriers, and ensure fertility and safety in the form of these nanotechnology, which leads to clinical use [3].

2. Liposomal and Vesicular Drug Delivery Innovations

The liposomal and vasicular drug delivery systems have greatly upgraded the accuracy and efficacy of medical distribution, increasing pharmacocyannetics and reducing systemic poisoning, offering unique abilities to encounter hydrophilic and hydrophobic drugs [4]. The diverse structural versatility of liposomes allows their surfaces to be modified with ligands or polymers for active targeting, which improves the accumulation of the drug in specific tissues and reduces adverse side effects [5].

Current research emphasizes the integration of novel liposomal compositions and manufacturing techniques to improve stability, drug loading efficiency, and controlled-proved behavior, the position of liposomes in the form of important vehicles in modern therapeutic [6]. These innovations include excitement-ex-ex-vesicles that release drugs under specific conditions, such as temperature or pH changes, enabling on-demand drug delivery on target sites [7].

In addition, the liposomal system has a variety of variations, including multilemeler vesicles, small universal vesicles, and large universal vesicles, each of which are suitable for separate clinical applications [8]. Researchers are also focused on raising the circulation time of lipid compositions and surface and by mononuclear phagocyte system to reduce uttake, thus prolonging systemic availability [9].

Extending beyond traditional liposomes, polymeric nanoparticles provide another vesicular platform, distributing drugs with precise size control and biodegradability, although their toxicity and environmental effects require a thorough evaluation [10]. In addition, programmable lipid nanopards represent a state-of-the-art approach, using modular design and domain-specific architecture to improve accurate targeting and better therapeutic results [11].

Table 1. Liposomal and Vesicular Drug Delivery Innovations.

Subsection	Description
Encapsulation and Pharmacokinetics	Liposomes and vesicles enable encapsulation of hydrophilic and hydrophobic drugs, enhancing pharmacokinetics, bioavailability, and reducing systemic toxicity [4].
Surface Modification for Targeting	Surface engineering with ligands or polymers enables active targeting and improved drug accumulation at pathological sites, minimizing adverse effects [5].
Formulation and Stability Improvements	Innovations in liposomal composition and production methods aim to increase drug loading, formulation stability, and controlled-release properties [6].
Stimuli-Responsive Systems	Development of liposomes responsive to temperature, pH, or other environmental triggers allows for site-specific, on-demand drug release [7].
Types of Liposomes	Liposomal systems include multilamellar vesicles, small unilamellar vesicles, and large unilamellar vesicles, each optimized for specific clinical needs [8].
Circulation and Immune Evasion	Optimization of lipid composition and surface charge improves circulation time and reduces recognition by the mononuclear phagocyte system (MPS), enhancing therapeutic availability [9].
Polymeric Nanoparticles	Serve as complementary vesicular systems with size control and biodegradability, though potential toxicity and environmental effects must be considered [10].
Programmable Lipid Nanoparticles	Cutting-edge nanocarriers designed with modular, domain-specific architecture for highly precise targeting and improved treatment outcomes [11].

3. Polymeric Nanoparticles and Programmable Lipid Systems

Polymeric nanopartan has emerged as a versatile carrier in drug distribution, which improves pharmacocinetics and therapeutic efficacy, due to the ability to increase a wide range of medical agents and release them in a controlled manner. A remarkable approach involves designing nanops up with pH-respondent linkage, such as the chiff base, enabling the release of selective drug in the acidic microelement of the tumor while maintaining stability in normal tissues [12].

Beyond the polymer system, programmable lipid nanoparts represent an important innovation, offering accurate targets through structural modifications and adaptable lipid compositions. These systems take advantage of modular architecture that can respond to physiological triggers or include specific ligands for receptor-medium delivery, can increase tissue specificity and reduce systemic side effects [13].

Recent researches have highlighted dextran-docosorubicin product-based nanops as effective pH-sensitive carriers, providing high drug-loading efficiency and controlled drug release, which are important to reduce poisoning and increase medical results in cancer treatments [13]. Such development underscores nanocheriors the convergence of material science and drug technology in crafting that are biocompatible and functional dynamic, which pave the way for individual drug applications [13].

4. pH-Responsive and PEGylated Nanoparticles for Targeted Therapy

PH-responded and peglated nanoparticles represent a large advancement in crossing biological barriers that limit drug distribution, especially in solid tumors. By exploiting acidic tumors microelement, pH-sensitive systems can trigger the drug release especially at the disease site, which reduces systemic poisoning [14]. Such targeted release not only enhances medical index, but also allows to accumulate high drug concentrations on a pathological site compared to traditional distribution systems [14].

Pegylation, the process of attaching polyethylene glycol chains to nanopartical surfaces, improves systemic circulation by reducing opsonization and uptake by reticuloendothelial system. This stearic stabilization is particularly important to achieve passive targeting through increased permeability and retention (EPR) effects, a strategy that is usually applied to cancer nanomedicine [14].

Recent innovations also highlighted the application of microobots and magnetically guided nanops up as emerging tools for site-specific distribution. These platforms can navigate through the body using external magnetic fields, allowing accurate drug localization while reducing off-target exposure [15]. Their clinical capacity is being actively examined for minimal invasive, targeted medical intervention [15].

Additionally, proniosomes provide a steady, pH-respondent vesicular formulation that is capable of converting to niosomes on hydration. These systems increase the entry efficiency and structural stability of the drug, which make them suitable for various delivery routes, including oral, transdermal and parental administrative [16].

Table 2. pH-Responsive and PEGylated Nanoparticles for Targeted Therapy.

Subsection	Description
pH-Responsive Nanoparticles	Designed to release drugs in response to acidic environments, particularly effective in targeting tumor tissues. This selective release improves therapeutic index and minimizes systemic toxicity [14].
PEGylation and Steric Stabilization	PEGylation (polyethylene glycol modification) enhances nanoparticle stability and prolongs systemic circulation by avoiding immune recognition and clearance, facilitating the EPR-based passive targeting mechanism [14].
Magnetically Guided Nanocarriers	Microrobots and magnetically directed nanoparticles offer external control for precise site-specific drug delivery, representing a promising strategy for minimally invasive cancer therapy [15].
Proniosomes with pH Responsiveness	Dry, stable vesicular systems that hydrate into niosomes at the target site. They offer improved drug loading, pH-sensitive release, and adaptability for oral, transdermal, and parenteral applications [16].

5. Effervescent Systems, Proniosomes, and Herbal-Based Drug Delivery

Their rapid disintegration, better patient compliance, and extended bioavailability [17] are used rapidly in oral drug distribution. These systems use acid-base reactions to produce carbon dioxide,

enable quick spread and facilitates better gastrointestinal absorption [18]. They are particularly valuable for distributing drugs that require rapid start or better solubility.

Proniosomes, which create niosomes on hydration, offer better chemical stability and ease of storage than traditional vesicular systems. Their application spreads many administration routes and has been effective in improving the distribution of poorly soluble or unstable drugs [18]. Structural structure and surfactant selection vest size, entry efficiency in the drug and release cannteix are important in tune.

Supplements for these systems, herbal-based formulation-like-Tribulus received from Terrestreis-have received traction to reduce their medicinal efficacy and toxicity. These plant-based approaches are particularly relevant in chronic treatments such as urolithiasis, where long-term security is necessary [19]. Including herbal agents in modern distribution systems pulls traditional and contemporary pharmacology, expands therapeutic toolkit for chronic and systemic diseases.

In addition, it is important to understand the interaction between nanopartical surfaces and biological environment. Studies suggest that blood protein can adsorb on the surface of the vesicular carrier such as liposomes, changing their pharmacocyannetics and biodistratation, thus affecting efficacy and safety profiles [20].

6. Extracellular Vesicles, Safety, and Translational Perspectives

Extraselular vesicles (EVS), including exosomes and microavasicals, have emerged as promising natural nanocherries for drug distribution due to their bio -transportation, ability to overcome biological barriers, and underlying targeting capabilities. They can encounter various types of medical agents and facilitate cell-to-cell communication, making them ideal for accurate drug [21]. Their ability to modify inflammation, distribute small molecules and maintain stability in biological environment connects their medical utility [21].

Liposomal carriers, a type of synthetic vasicular system, have long served as a foundation for drug distribution technologies. Their structural imitation of the biological membrane allows for efficient encapsulation of both hydrophilic and lipophilic drugs. Liposome has performed better pharmacocynetic profiles and reduces systemic poisoning, which paves the way for clinically approved yogas [22]. Their design affects the growth of flexibility EV-mimic platforms.

Smart nanocarers such as Mesoporus silica nanoparticles are also examined for their tuniable por structures and high surface area, allowing site-specific drug loading and controlled release. In colorectal cancer therapy, these systems increase tumor accumulation and selective cytotoxicity, improving medical results, decreasing systemic risk, [23].

The broader landscape of nano technology applications in cancer treatment highlights the developed role of targeted drug delivery. From diagnostics to therapeutics, Nanoscale systems provide equipment to improve efficacy, reduce toxicity and adapt to treatment protocols based on patient-specific characteristics [24].

Table 3. Extracellular Vesicles, Safety, and Translational Perspectives.

Subsection	Description
Extracellular Vesicles (EVs)	EVs, such as exosomes and microvesicles, are natural nanocarriers known for their biocompatibility and ability to cross biological barriers. They enable cell-to-cell communication and can deliver small molecules for precision medicine [21].
Liposomal Drug Carriers	Liposomes, synthetic vesicles mimicking biological membranes, have a strong record of enhancing drug solubility and reducing toxicity. Their success in clinical formulations continues to inspire EV-mimetic drug delivery systems [22].
Mesoporous Silica Nanoparticles (MSNs)	MSNs offer high drug loading capacity due to their porous architecture. In colorectal cancer therapy, they provide tumor-specific accumulation, controlled release, and reduced systemic toxicity [23].
Role in Cancer Nanomedicine	Nanocarriers are integral to personalized oncology, enabling both diagnostic imaging and therapeutic delivery. Their ability to improve efficacy and customize treatment regimens is transforming clinical approaches [24].

Translational and Regulatory Aspects	Successful clinical translation requires addressing scalability, long-term safety, and regulatory hurdles. Strategies include optimizing formulation reproducibility and meeting commercial stability standards [25].
--------------------------------------	---

For translation in clinical settings, scalability, reproduction and regulatory compliance are important. Recent studies emphasize strategies to reduce the difference between laboratory research and commercial drug products and to reduce the difference between laboratory research and commercial drug products by evaluating long -term security [25].

Conclusion

The advancement of drug distribution platforms has revolutionized therapeutic consequences by increasing site-specific distribution, reducing systemic poisoning and enabling accurate medicines. This article investigated a diverse range of Smart Nanocherirs and BioinSpeed Systems- provides each unique mechanical advantage. Liposomes and vasicular systems have greatly progressed, improving pharmacocinetics and patient compliance. Polymeric nanops and programmable lipid constructions have expanded more expansion capabilities for controlled and responsible drug release. In addition, pH-sensitive and peglated nanocarers provide strategic benefits in solid tumor targeting, which improves drug bioavailability and medical indices. Innovations in magnetic nanotechnology and microbotic systems present a future direction for navigation-based drug release in inaccessible sites. At the same time, the effects provide the effects to the effects and pronouns versatile and scalable oral yogas, while herbal-based strategies strengthen the ability of natural agents in modern pharmaceutics.

Extraselular vesicles, with their endogenous origin and proficiency targets, brid down the gap between synthetic systems and biological compatibility, adding depth to translation and safety structure. Collectively, these smart drug delivery techniques not only address the current boundaries of traditional medical science, but also pave the way for the next generation, patient-specific treatment paradigms. Continuous interdisciplinary cooperation and clinical verification will be necessary to exploit their full potential.

References

1. Sengar, A. (2025). Advancements in Targeted Drug Delivery: Innovations in Liposomal, Nanoparticle, and Vesicular Systems. *Int J Bioinfor Intell Comput*, 4(2), 1–9.
2. Sengar, A. (2024). Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care. *International Journal of Advanced Nano Computing and Analytics*, 3(2), 56–67.
3. Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. *Nature Reviews Cancer*, 5(3), 161–171.
4. Sengar, A. (2025). Liposomes and Beyond: Pioneering Vesicular Systems for Drug Delivery. *Journal of BioMed Research and Reports*, 7(1), 1–6. <https://doi.org/10.59657/2837-4681.brs.25.124>
5. Alavi, M., & Karimi, N. (2017). Application of various types of liposomes in drug delivery systems. *Advanced Pharmaceutical Bulletin*, 7(1), 3–9.
6. Sengar, A. (2025). Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive Introduction. *J Emerg Med OA*, 3(1), 1–5.
7. Akhter, S., Ahmad, M. Z., Ahmad, F. J., Storm, G., & Alvi, M. M. (2013). Advances in liposomal drug delivery: A review. *Current Drug Delivery*, 10(5), 546–561.
8. Tseu, G. Y., & Kamaruzaman, K. A. (2023). A review of different types of liposomes and their applications. *Molecules*, 28(3), 1498.
9. Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021). Liposome composition in drug delivery: design, synthesis, characterization, and clinical application. *Advanced Drug Delivery Reviews*, 176, 113851.
10. Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., & Pires, B. (2020). Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. *Molecules*, 25(16), 3731.

11. Liu, Z., Chen, J., Xu, M., Gracias, D. H., Yong, K.-T., Wei, Y., & Ho, H.-P. (2024). Advancements in programmable lipid nanoparticles: Exploring the four-domain model for targeted drug delivery. arXiv preprint arXiv:2408.05695.
12. Song, J., Xu, B., Yao, H., Lu, X., & Tan, Y. (2021). Schiff-linked PEGylated doxorubicin prodrug forming pH-responsive nanoparticles with high drug loading and effective anticancer therapy. *Frontiers in Oncology*, 11, 701.
13. Zhang, X., Zhang, T., Ma, X., Wang, Y., & Lu, Y. (2020). The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system. *Asian Journal of Pharmaceutical Sciences*, 15(5), 605–614.
14. Jain, R. K., & Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. *Nature Reviews Clinical Oncology*, 7(11), 653–664.
15. Landers, F. C., Hertle, L., Pustovalov, V., Sivakumaran, D., Brinkmann, O., Meiners, K., ... & Nelson, B. J. (2025). Clinically ready magnetic microrobots for targeted therapies. arXiv preprint arXiv:2501.11553.
16. Sengar, A., Saha, S., Sharma, L., Hemlata, Saindane, P. S., & Sagar, S. D. (2024). Fundamentals of proniosomes: Structure & composition, and core principles. *World Journal of Pharmaceutical Research*, 13(21), 1063–1071.
17. Sengar, A., Tile, S. A., Sen, A., Malunekar, S. P., Bhagat, D. T., & Thete, A. K. (2024). Effervescent tablets explored: Dosage form benefits, formulation strategies, and methodological insights. *World Journal of Pharmaceutical Research*, 13(18), 1424–1435.
18. Sengar, A. et al. (2025). Advancing urolithiasis treatment through herbal medicine: A focus on *Tribulus terrestris* fruits. *World Journal of Pharmaceutical Research*, 14(2), 91–105.
19. Yáñez-Mó, M., Siljander, P. R., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., ... & De Wever, O. (2015). Biological properties of extracellular vesicles and their physiological functions. *Journal of Extracellular Vesicles*, 4(1), 27066.
20. Chonn, A., Semple, S. C., & Cullis, P. R. (1992). Association of blood proteins with large unilamellar liposomes in vivo. *Journal of Biological Chemistry*, 267(26), 18759–18765.
21. Puglia, C., Bonina, F., & Puglisi, G. (2004). Evaluation of in-vivo topical anti-inflammatory activity of indometacin from liposomal vesicles. *Journal of Pharmacy and Pharmacology*, 56(10), 1225–1232.
22. Gregoriadis, G., & Florence, A. T. (1993). Liposomes in drug delivery. *Drug Development and Industrial Pharmacy*, 19(6), 785–804.
23. Mann, R. A., Hossen, M. E., Withrow, A. D. M., Burton, J. T., Blythe, S. M., & Evett, C. G. (2024). Mesoporous silica nanoparticles-based smart nanocarriers for targeted drug delivery in colorectal cancer therapy. arXiv preprint arXiv:2409.18809.
24. Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007). Nanotechnology applications in cancer. *Annual Review of Biomedical Engineering*, 9, 257–288.
25. Sengar, A. (2025). Advancements in Liposomal and Nanoparticle-Based Targeted Drug Delivery. *Pharm Res J*, 2(1), 1–5.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.